NL-OMON40619已完成2 期
Axetis Inert Coronary Stent System First in Man (FIM) Clinical Investigation - AXETIS FIM
Axetis AG0 个研究点目标入组 35 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •*18 to 85 years
- •*Evidence of myocardial ischemia without elevated Troponin / cardiac biomarkers (e.g. stable or unstable angina, silent ischemia demonstrated by positive territorial functional study). NSTEMI patients are allowed, as long as Troponin is within the normal limits before the start of the procedure.
- •*The patient has a planned intervention of up to two de-novo lesions in two different vessels (previously untreated vessels)
- •*Lesion must have a visually estimated diameter stenosis of *50% and <100%.
- •*Lesion length must be * 28 mm
- •*RVD must be between 2.4 and 3.8 mm
- •*Written informed consent
- •*The patient and the patient*s physician agree to the follow-up visits including angiographic follow-up and OCT control at 6 months
排除标准
- •- Evidence of ongoing acute myocardial infarction in ECG and or elevated cardiac biomarkers prior to procedure
- •- LVEF <30%
- •- Platelet count <100,000 cells/mm3 or >400,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis)
- •- Known renal insufficiency (e.g., eGFR <60 ml/kg/m2 or serum creatinine level of >2.5 mg/dL, or subject on dialysis)
- •- History of bleeding diathesis or coagulopathy
- •- The patient is a recipient of a heart transplant
- •- Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet medication specified for use in the study (clopidogrel, prasugrel, ticagrelor and ticlopidine) or stainless steel
- •- Other medical illness (e.g. cancer, stroke with neurological deficiency) or known history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy
- •- Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
- •*Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter
- •*Target lesion in left main stem.
- •*Target lesion involves a side branch > 2.0mm in diameter
- •*Aorto-ostial target lesion (within 3 mm of the aorta junction).
- •*Total occlusion or TIMI flow 1, prior to wire crossing
- •*The target vessel contains visible thrombus
- •*Restenotic lesion
- •*Located within an arterial or saphenous vein graft
- •*Target vessel with previously placed stent or with graft
- •*Treatment of more than 1 lesion in one vessel, or treatment of more than two lesions
研究者
相似试验
Unknown
不适用
Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM)Native Coronary Artery StenosisNCT02317081Axetis AG35
已完成
不适用
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigatiomyocardial ischemia and coronary atherosclerosis10011082NL-OMON40746QVANTEQ14
已完成
不适用
STENTYS Coronary Stent System Clinical Trial in Patients with Acute Myocardial InfarctioHeart-attack10011082Myocardial InfarctionNL-OMON38520STENTYS120
已完成
4 期
XIENCE V India: XIENCE V Everolimus Eluting Coronary Stent System (EECSS) India Post-Marketing RegistryCTRI/2008/091/000213Abbott Vascular1,000
Unknown
2 期
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary StentCoronary Artery DiseaseMyocardial IschemiaNCT02189499Amaranth Medical Inc.42